A recent study highlights the diagnostic potential of interferon-stimulated gene 15 (ISG15) muscle expression in dermatomyositis. This research could enhance diagnostic accuracy for this rare autoimmune disease.

Orsini will serve as the specialty pharmacy partner for Priovant's LISRAYA™ (brepocitinib), enhancing patient access to this innovative treatment. The drug was evaluated in the VALOR study, the largest placebo-controlled trial for dermatomyositis, indicating significant advancements in rare disease therapies.

Priovant Therapeutics secures FDA approval for its dual TYK2/JAK1 inhibitor, marking a significant milestone as the first approved treatment for adult dermatomyositis (DM). The approval is supported by data from the largest DM study ever conducted, the Valor trial, allowing use without restrictions based on disease activity or previous treatments.

A case study highlights the recovery of a patient with fulminant anti-nuclear matrix protein 2 antibody-positive dermatomyositis, characterized by massive anasarca and respiratory failure, after prolonged immunosuppression and rehabilitation. This research underscores the potential for recovery in severe cases of this rare autoimmune disease.

A recent case report details a pediatric patient with AQP4+ neuromyelitis optica spectrum disorder (NMOSD), MDA5+ clinically amyopathic dermatomyositis, and secondary hemophagocytic lymphohistiocytosis (sHLH). This study contributes to the understanding of these rare conditions and their clinical presentations.